ALVOTECH news, videos and press releases - Page 5
For more news please use our advanced search feature.
ALVOTECH - More news...
ALVOTECH - More news...
- Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04
- Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04
- Alvotech and Islandsbanki enter into Market Making Agreement for Shares Trading on Nasdaq Iceland
- Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
- Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
- Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®
- Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®
- Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)
- Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)
- Alvotech to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
- Alvotech Announces Changes to the Leadership Team
- Alvotech Announces Changes to the Leadership Team
- Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update
- Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update
- Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
- Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
- Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET
- Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET
- Alvotech Completes $100 Million Convertible Bond Private Placement
- Alvotech Completes $100 Million Convertible Bond Private Placement
- Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
- Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
- Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02
- Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02
- Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
- Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
- Alvotech to Participate in Jefferies Healthcare Conference
- Alvotech to Participate in Jefferies Healthcare Conference
- SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the Firm
- Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe
